Clinical Trials on Leukaemia During Childhood or Adolescence in Singapore

Total 9 results

KK Women's and Children's Hospital
National University Hospital, Singapore; Singapore General Hospital

Recruiting

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR

Singapore
National University Hospital, Singapore

Recruiting

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | CAR T-Cell-Related Encephalopathy Syndrome | Refractory Leukemia

Singapore
National University Hospital, Singapore

Recruiting

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. (ALaCART)

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | CAR T-Cell-Related Encephalopathy Syndrome

Singapore
National Hospital Organization Nagoya Medical Center

Recruiting

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Acute Lymphoblastic Leukemia | Down Syndrome | Childhood Cancer

Taiwan, Thailand, Hong Kong, Singapore, Malaysia, Japan
University of Southampton
National University Hospital, Singapore; Singapore Institute for Clinical Sciences and other collaborators

Enrolling by invitation

NiPPeR Randomised Trial - Child Follow Up Study (NiPPeR Child)

Neurobehavioral Manifestations | Allergy | Microbial Colonization | Growth Disorders | Atopic Dermatitis | Obesity, Childhood | Metabolic Disturbance | Cognition | Lifestyle | Breastfeeding | Nutrition, Healthy | Atopy

Singapore, United Kingdom, New Zealand
Novartis Pharmaceuticals

Terminated

Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

Gouty Arthritis

China, Poland, Singapore, Argentina
Novartis Pharmaceuticals

Completed

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study (β-RELIEVED)

Acute Gout

Colombia, Switzerland, Germany, Russian Federation, Singapore, Australia, Belgium, Canada, Estonia, Guatemala, Latvia, Lithuania, Mexico, Norway, Poland, Sweden, Ukraine
Novartis Pharmaceuticals

Completed

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Gouty Arthritis

Colombia, Spain, Taiwan, Russian Federation, Guatemala, Belgium, United States, Argentina, Czechia, Germany, Hungary, Poland, Portugal, Singapore, Slovakia, South Africa, Turkey, United Kingdom
Novartis Pharmaceuticals

Completed

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Gout

United States, Colombia, Russian Federation, Taiwan, Argentina, Turkey, Germany, Singapore, Spain, Hungary, Guatemala, Poland, South Africa, Slovakia, Portugal, Belgium, Czechia, United Kingdom

Clinical Trials on Leukaemia During Childhood or Adolescence in Singapore

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations